135 filings
Page 3 of 7
SC 13D/A
4vii i9ubkv5gh5y
20 Jul 22
Silence Therapeutics / Griffiths Richard Ian ownership change
4:00pm
SC 13D
qpwo5f1
15 Jun 22
Silence Therapeutics / Griffiths Richard Ian ownership change
4:31pm
6-K
mup5tq
14 Jun 22
Current report (foreign)
5:20pm
6-K
jjbt3ln3qj5 70up
16 May 22
Current report (foreign)
8:31am
6-K
q6phz0wb
16 May 22
Silence Therapeutics plc Notice of Annual General Meeting
8:30am
6-K
2b55e l92b
25 Apr 22
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
8:31am
6-K
lrk8x eqh7cfem
4 Apr 22
Current report (foreign)
8:31am
6-K
zabos p7g3wf0g4
23 Mar 22
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
8:30am
6-K
ev83f iuhf
22 Feb 22
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
6:52am
SC 13G
facrnjzwj0m6v2wiyl
14 Feb 22
Silence Therapeutics / Quested Robert ownership change
4:57pm
SC 13G
td5ey2vzy54
14 Feb 22
Silence Therapeutics / Griffiths Richard Ian ownership change
4:54pm
SC 13G/A
nn0rc224j3 1l91v
10 Feb 22
Silence Therapeutics / Lombard Odier Asset Management ownership change
4:44pm
6-K
52sei2vbohupyim
9 Feb 22
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study
7:30am
SC 13G
i3uivo6dn3t4tg 86
7 Feb 22
Silence Therapeutics / Mallinckrodt ownership change
4:01pm
SC 13G
9opd4rh9qe2ivh9tdq
27 Jan 22
Silence Therapeutics / GOLDMAN SACHS ownership change
2:51pm
6-K
jsm9 whnq4z2vg8vt8
13 Dec 21
Current report (foreign)
6:01am
6-K
5fqgnbk8
26 Nov 21
Current report (foreign)
6:23am
6-K
ia3e4f rqp50
16 Nov 21
Current report (foreign)
6:03am
6-K
q9l97dlo
1 Nov 21
Results of General Meeting
5:30pm